AIMS: To establish: 1) whether motor deficits in acute stroke improve more in patients taking donepezil, relative to placebo, for 12 weeks; 2) whether brain functional MRI changes as a result of donepezil after 12 weeks.
Stroke is a major personal and social burden, being the commonest cause of severe adult disability. Recovery has been shown in animal models to be dependent upon adequate levels of acetylcholine within the brain - which in stroke is likely to be deficient. This is because acetylcholine-producing nerve cells in the brain are often damaged by strokes. Consequently, the investigators hypothesise that recovery may be improved by boosting acetylcholine levels in the brain - that can be readily achieved by treating with donepezil.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Charing Cross Hospital, Imperial College Academic Health Science Centre
London, United Kingdom
Change in Upper Extremity Fugl-Meyer Motor Score (out of 66) over 12 weeks
Time frame: 12 weeks
Change in Functional MRI Connectivity and Task-related activation (relative % BOLD signal change) over 12 weeks
resting-state / activation-related fMRI
Time frame: 12 weeks
Number and type of participants with adverse events
Self-reported / Questionnaire
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.